Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...

On Feb. 27, Blackstone disclosed that Rodney Zemmel – a long-time Senior Partner at McKinsey, who served as the global leader of both McKinsey Digital and the firm’s AI Transformation initiatives – ...

AN ALZHEIMER’S drug hailed as a ‘miracle’ medicine for dementia may cause life-threatening brain bleeds in a third of ...

US-based Eli Lilly's Kisunla drug and Japanese company Eisai's Leqembi (below), two breakthrough drugs for the diagnosis and ...

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...

The UK’s National Institute for Health and Care Excellence (NICE) has issued further draft guidance reaffirming its decision ...

What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

All had early symptomatic Alzheimer's disease and elevated amyloid ... This study was sponsored by Eli Lilly and Company. Sims and 15 co-authors were employees of and shareholders in Eli Lilly ...

Lilly and AZ have a rival in the BACE field – Merck's MK-8931 is currently in a phase 2/3 study treating patients with mild to moderate Alzheimer's. BACE offers hope ...

Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure, which is ...